Association of follistatin and cytochrome p450 side-chain cleavage enzyme with polycystic ovarian syndrome

Fouzia Nazir1, S. Inayatullah2, S. Jalali3

1King Faisal Medical Complex Taif, Saudi Arabia, 2Department of Biochemistry, Hazara University, Mansehra, Pakistan, 3Department of Biological Sciences, Quaid-e-Azam University, Islamabad, Pakistan

Address for correspondence:
Dr. Fouzia Nazir, King Faisal Medical Complex, Taif, Saudi Arabia.
E-mail: nazirs2000@hotmail.com

Introduction

Women with polycystic ovarian syndrome (PCOS) produce an abnormal amount of male hormones known as androgens. Among disorders of the reproductive age group, PCOS requires particular attention[1] because 5–10% of the pre-menopausal women are affected by PCOS and its major manifestations are chronic anovulation and hyperandrogenism.[2]

Clinical characteristics and histological features should be analyzed for the symptoms of obesity, bleeding, infertility, as well as miscarriages.[3,4] Biochemically, PCOS can be described with hyperandrogenism and elevated serum luteinizing hormone (LH) as well as hyperinsulinemia. Hyperinsulinemia has been documented as the cause of hyperandrogenism in PCOS women.[5-7] Another study suggested that PCOS increases the risk of cardiovascular as well as diabetic events.[8] The main cause that results in PCOS is still known; however, insulin resistance, inflammation, and genes are associated with excess androgen production in women suffering from PCOS. PCOS can be explained by different pathways. Those pathways include metabolic as well as regulatory avenues and genes should also be assessed for the identification of candidate genes.[9] The familial clustering phenomenon of PCOS cases has been studied for the past 30 years and evidence has suggested that PCOS propagates in the family and the risk for the family members increases up to the extent of 50% but the mode of transmission has not been agreed yet.[10-12,14-16] The possible candidate genes have been analyzed previously,[17] involved in the pathways of steroid hormones, metabolism and action, gonadotrophic action, obesity and energy regulation, and insulin action.[17-19] Primers were designed to amplify these possibly polymorphic sites, that is, short tandem repeat polymorphism (STRPs) and single nucleotide polymorphism
(SNPs), which were located within or adjacent to the candidate genes.\cite{20}

Power estimates can describe the linkage between markers and disease-susceptibility locus as well as the in formativeness of markers. High-density genetic maps have been created which could facilitate positional cloning projects.\cite{21,22} The CYP11A mRNA was observed to be more abundant in the theca cells of individuals with polycystic ovary syndrome as compared to the theca cells of normal individuals. The potential of developing an association is triggered by different factors, and the medical practitioners should evaluate the locus genotypes for the possible penetration of the disease.\cite{23} Candidate genes known for PCOS include genes involved in the biosynthesis of androgens, action of insulin, and gonadotrophin.\cite{24-28} Genes for different receptors have also been reported as PCOS candidate genes. The key genes associated with dysregulation of androgen production in women include CYP11A1, CYP21, CYP17, and CYP19. To study the genetic basis of PCOS, linkage and association studies can be a valid tool.\cite{29} The objective of the present study involves the determination of the Mendelian inheritance of trait, segregation of microsatellite markers for particular loci and determination of the genetic basis of PCOS using linkage analysis and association study strategies.

**Materials and Methods**

**Diagnosis of PCOS**

PCOS diagnosis was carried out using ultrasound and biochemical analysis of these families. Women with menstrual problems, hirsutism, obesity, and infertility were designated as polycystic ovarian syndrome (PCOS) women. Phenotype of the six families described in the present study was hirsutism with ferriman gallwey scoring, obesity by body mass index and waist: hip ratio, diagnosis of polycystic ovarian syndrome individual with Rotterdam criteria (2003).

Women diagnosed with polycystic ovarian syndrome (PCOS) at Prof. Dr. Saad Raana Gynecological Advisory Centre, Islamabad were interviewed to record information required for the present study. Extensive pedigrees were drawn for the genetic studies. Probands were interviewed to trace back the disease in each family. In the context of genetic studies, probands are individuals that initiate the study and research process in a family. The pedigrees were constructed for at least up to five generations depending on how much the proband could recollect about the disease in the members of the family. There were 121 women from six families, of which 17 women died and 42 were not available for interview. A total of 62 women agreed to cooperate. Blood samples were collected from 62 women in sterile containers containing potassium ethylene diamine tetra acetic acid (EDTA) prepared for DNA extraction. Written consent was taken from all the subjects involved in the study.

**DNA extraction from whole blood**

DNA was extracted from whole blood using standard procedure.\cite{19}

**Polymerase chain Reaction (PCR)**\cite{20}

Microsatellite markers for the known loci of PCOS as described in Table 1 were obtained from research genetics, Inc. (USA). The cytogenetic information was obtained from genome databases including gdb.org and marshmed.org.

The polymerase chain reaction was performed using the following reaction mixture:

- Sample DNA 1 µl (microliter)
- 10X PCR buffer 2.5 µl
- MgCl$_2$ (Magnesium Chloride) 1.5 µl
- Deoxyribonucleotide triphosphate (dNTPs) 0.5 µl
- Forward and reverse primer 0.3 µl
- Taq DNA polymerase 0.3 µl
- PCR water 20.1 µl

A thermo-cycling environment was used for obtaining the mixture as follows:

- 5 min of 90°C for template denaturation
- 40 cycles of amplification each consisting of 3 steps
  - 1 min at 90°C for DNA denaturation
  - 1 min at 55–57°C for primer annealing
  - 1 min at 72°C for extension of complimentary
- DNA strand
- 10 min at 72°C for un-extended strands left
- PCR was performed subsequently.

**Agarose gel electrophoresis**

PCR products were resolved on 2% agarose gel.

**Poly acrylamide gel electrophoresis (PAGE)**\cite{21}

The amplified products were resolved on 8% non-denaturing polyacrylamide gel. Electrophoresis was carried out at 100 volts for 90 min and the gel was stained with ethidium bromide (10 mg/ml) solution for visualization on UV trans-illuminator. The gel was photographed by using a digital camera DC120 (Kodak, USA).

**Genetic and primer database analysis**

Analysis of microsatellite markers for the known loci as entitled in Table 1 was performed by PCR and gel electrophoresis. Amplified products using microsatellite markers were visualized by placing the ethidium bromide-stained gel on a UV trans-illuminator and genotypes were assigned by visual inspection. Homozygosity and heterozygosity were recorded and alleles were numbered concerning the origin.
Table 1: 37 candidate gene panel for PCOS

| Marker locus | Gene symbol | Candidate gene | Distance in centimorgans (cM) | Chromosome location |
|--------------|-------------|----------------|-------------------------------|---------------------|
| Steroid hormone | D1S514 | HSD3II+2 | 3ΒHydroxysteroid dehydrogenase, type I and II | <1 | lp31.1 |
|               | D8S1821 | STAR | Steroidogenic acute regulatory protein | <2 | 8_1_>.1:2 |
|               | D9S809 | HSD17B3 | 17ΒHydroxysteroid dehydrogenase type III | <1 | 9q22 |
|               | DIOS192 | CYPI7 | CYP 17cytochrome P450 17 hydroxylase/17 20 desmolase | <1 | 10q24.3 |
|               | D15S519 | CYPI1A | CYP 11A cytochrome P450 side chain cleavage enzyme | 0 | 15q 23-24. |
|               | DI5S520 | CYP II A | CYP 11A cytochrome P450 side chain cleavage enzyme | 0 | 15q 23 to 24 |
|               | DJ7S934 | HSD17I.H | 17ΒHydroxysteroid dehydrogenase type I | <2 | 17q11-21 |
|               | HSD17B2 | HSD17I I | 17ΒHydroxysteroid dehydrogenase typeI | 0 | 16q24.2 |
| Gonadotropin action | D2S235 | ACTR1 | Activin receptor 1 | <1 | 12q13.12 |
|               | D2S 1352 | LHCGR | Luteinizing hormone/choriogonadotropin receptor | <2 | 2p21 |
|               | D2S293 | INHB 11 | Inhibin II B | <2 | 2cen-2q13 |
|               | D2S163 | INHA | Inhibin A | <1 | 2q33.34 |
|               | D3S 1298 | ACTR2B | Activin receptor 213 | <1 | 3q22.2 |
|               | D5S-623 | FS | Follistatin | <0.5 | 5p14 |
|               | D5S-822 | FS | As above | <1 | 5p14 |
|               | INHBA | INHBA | inhibin BA | 2 | 7p13-15 |
|               | D5S474 | FS | Follistatin | <2 | 5p14 |
|               | DI2S691 | INHC | Inhibin C | <1 | 12q13 |
|               | DI2S347 | ACTR1 | Activin receptor 1 | <1 | 12q13.12 |
|               | DJ7S153 | SHBG | Sex hormone-binding globulin | <1 | 1p13.2 |
|               | DJ8S474 | MADH4 | Mothers against decapentaplegic homolog 4 | <1 | 18q21 |
| Obesity and energy regulation | DJ8S64 | MC4R | Melanocortin 4 receptor | <3 | 18q21.32 |
|               | D9S1875 | OB | Leptin | 0.2 | 7q31.3-32.1 |
|               | DIS198 | OBR | Leptin receptor | 0.5 | 1q31 |
|               | D2S1831 | POMC | proopiromelanocortin | <! | 2p23 |
|               | DJ9S161 | UCP2&3 | Uncoupling protein 2 and 3 | <4 | 11q13 |
| Insulin action | IGF 1 | IGFI | Insulin-like growth factor I | 0 | 12q22-23 |
|               | IGF-IR | IGFI R | Insulin-like growth factor receptor | 0 | 15q25-26 |
|               | D7S.S19 | IGFBP 1&3 | Insulin-like growth hormone binding protein 1 and 3 | 1 | 7p13-7p11 |
|               | INSR | INS R | Insulin receptor | 4.2 | 19p13.3 |
|               | DJ9S216 | INSR | Insulin receptor | 1.2 | 19p13.3 |
|               | DJ9S844 | INSR | Insulin receptor | 3.6 | 19p13.3 |
|               | DJ9S222 | INSR | Insulin receptor | 7.2 | 19p13.2 |
|               | DJ9S391 | INSR | Insulin receptor | 14 | 19p 13.2 |
|               | DJ9S865 | INSR | Insulin receptor | 1.2 | 19p13.3 |
|               | DJ9S096 | INSR | Insulin receptor | 3.6 | 19p13.3 |
|               | DJ9S840 | INSR | Insulin receptor | 7.2 | 19p13.2 |
|               | DJ9S212 | INSL3 | Leydig Insulin-like protein 3 | <1 | 19p13.3 |
|               | DJ9S410 | INSL3 | Leydig insulin-like protein 3 | <1 | 19p13.3 |
|               | D2S2647 | IRS1 | Insulin receptor substrate 1 | 0 | 2q36-37 |
|               | D3S1263 | PPARG | Peroxisome proliferators activated receptor gamma | <0.2 | 3p25-24.2 |
Statistical analysis

Association between microsatellite markers for the known loci of PCOS and the disease was carried out using Chi-square analysis.

Results

Pedigree analysis

The six pedigrees proceeded for the present study indicated recessive mode of inheritance. Pedigrees of the strongly associated families, that is, family 2 and family 5 have been described in Figures 1 and 2, respectively. Phenotype of PCOS women in current study exhibit significant hirsutism, obesity, acne, acanthosis nigricans and fertility and menstrual issues in 50% moderate hirsutism and acanthosis nigrican in 52.5% women. Family 2 showed strong association with D5S822 at locus ($X^2 = 4.89; P < 0.05$) while family 5 depicted strong association with D15S519 ($X^2 = 7.78; P < 0.01$). Family 1, 3, 4, and 6 showed weak association with different markers [Tables 2 and 3].

Association study results

Strong and weak association of different families has been described in Tables 2 and 3.

Family 1

There is no significant association of allele 1 with marker D19S212 but there is the presence of a weak association ($X^2(1) = 2.25, P > 0.10$) in the transmission of allele 1 with marker D19S212 (19p13.1 INSL3, Leydig insulin-like protein 3).

Figures 3 and 4 show the Acrylamide gel photographs of markers for chromosomes in different families to investigate the affected, normal and positioning of each individual. It was observed that 7 individuals that were affected ranged from 4 to 9 and 7 normal individuals ranged from 2 to 6. Two types of marriages were observed in these pedigrees (i) a marriage between PCOS and normal and (ii) between normal and non-PCOS. In both marriages, the data was assembled regarding the inheritance of PCOS and non-PCOS conditions in the offspring. Data revealed a 1:1 Mendelian ratio between normal and non-PCOS marriages [Table 4] while a Mendelian ratio of 3:1 has been observed in marriages between normal and PCOS individuals [Table 5].
Table 2: Association of microsatellite markers with families of PCOS

| Family | Gene and marker | PCOS individuals | Genotype | Homozygosity | Non-PCOS individuals | Genotype | Homozygosity |
|--------|----------------|-----------------|----------|--------------|-----------------------|----------|--------------|
| 1      | INSLR (D19S212)| III-6, IV-1, IV-7| 1–1 (5) | 1–1 (5)      | IV-3, II-4, IV-9       | 1–1 (1) | 1–1 (1)      |
|        |                | IV-14, IV-17    | 2–2 (1) | 2–2 (1)      |                       | 1–2 (2) |              |
|        |                | V-6             | 1–2 (1) |              |                       |          |              |
|        |                | V-2             |          |              |                       |          |              |
| 2      | FS (D5S822)    | II-14, III-16, III-4| 1–1 (3) | 1–1 (3)      | II-17, II-7           | 1–2 (2) |              |
|        | INHB β (D2S293)| IV-1, IV-9, IV-10| 1–2 (3) |              |                       | 1–2 (4) |              |
|        |                | IV-4, IV-13     | 1–1 (2) |              |                       | 1–1 (1) |              |
|        |                | II-12           |          |              |                       | 1–1 (1) |              |
| 4      |                | III-15          | 1–2 (1) |              |                       | 1–3 (7) |              |
|        |                | IV-6            | 1–3 (1) |              |                       |          |              |
| 5      | CYP11A (D15S519)| III-6, III-10, IV-10| 1–1 (5) | 1–1 (5)      | III-2, III-3, IV-9    | 1–1 (1) |              |
|        |                | IV-12, IV-16    | 1–1 (5) |              |                       |          |              |

Numeric numbers indicate the position of individuals in the corresponding pedigree

Table 3: Statistical analysis of associated markers

| Family | Marker | X² value | Probability | Association |
|--------|--------|----------|-------------|-------------|
| 1      | D19S212| 2.25     | P<0.10      | Weak association |
| 2      | D5S822 | 4.89     | P<0.05      | Strong association |
| 3      |        | -        | -           | No association |
| 4      | D2S293 | 2.85     | P>0.05      | Weak association |
| 5      | D15S519| 7.78     | P<0.01      | Strong association |
| 6      | D19S391| 3.45     | P<0.05      | Weak association |

Discussion

A polycystic ovarian syndrome is considered a complex disorder in a clinical setting. The present study showed autosomal mode of inheritance in all families. Current study describes that there is a strong association of PCOS locus at chromosome 5 with marker D5S822 (P<0.05) in family 2 for allele 1 [Tables 1-5]. A study [18,22,23] involved families from European descent (n=90), Caribbean descent (n=5), Mexican descent (n=2), African-American descent (n=1), and Asian-Indian descent (n=1). The association between PCOS and alleles for four markers (D5S474, D5S822, D5S623, and the SNP in exon 6) was carried out. TDT analysis revealed that 2 markers with the highest X² values were the exon 6 variant (allele 1, X²=5, P=0.025) and the D5S623 (allele 11, X²=4.26, P=0.039). The expression level of follistatin between PCOS and control subjects was compared but no substantial difference was found. The present study highlighted that PCOS are a complex genetic trait requiring immediate medical attention in Pakistan. Current research indicated a very strong association of PCOS locus with marker D15S519 at chromosome 15 for allele 1 (P<0.01) in the case of family 5 [Table 2]. This marker is derived from the genetic region of CYP11A which has been involved previously in the etiology of PCOS [19]. Their association data indicated that allele variants of CYP11A mediate the development of hyperandrogenemia, which, in turn, is associated with PCOS and hirsutism. [24] Results of family 6 indicated that there is a weak association of PCOS locus at chromosome 19 with marker D19S391 (P=0.05) for allele 1. While a very weak association of PCOS locus at marker D19S212 for allele 1 in the case of family 1 has been observed (P>0.01) [Table 3]. Marker D19S391 has been derived from insulin receptor gene locus while marker D19S212 has been derived from the INSL3 region which represents Leydi insulin-like protein 3. Similar research [31,32] revealed that insulin receptor gene marker D19S884 was significantly associated with PCOS (P=0.001). They suggested that the susceptibility gene for PCOS was located...
on chromosome 19p13.3 in the insulin receptor region and insulin-stimulated androgen secretion from the ovarian stroma. INSR function in the ovary is likely involved in the gender susceptibility of PCOS. Another demonstration revealed that a D19S884 allele shows significant evidence for linkage and association specific to a phenotype of PCOS. A study indicated the involvement of the insulin receptor gene by taking into consideration the tyrosine kinase domain of the insulin receptor gene. They studied 22 patients with PCOS but no abnormalities have been indicated. Molecular scanning of the entire coding region of the gene in 24 hyperinsulinemia subjects was carried out with PCOS but no significant mutation has been detected. They concluded that mutation of the insulin receptor gene is, therefore, unlikely to be a major cause of insulin resistance in PCOS. A similar opinion was given by another study in their study. Present study showed secondary amenorrhea in significant number of women which is indicative of anovulation which depicts problem in their steroid and insulin metabolism. Family 2 revealed strong association with D5S822 which is follistatin gene marker. Follistatin is involved in autocrine, paracrine and endocrine control of ovarian folliculogenesis.

Family 5 showed strong association with D15S519 which is involved in steroid hormone control. Candidate genetic loci including CYP11A, CYP17, follistatin, and insulin receptor have been identified by mutation detection, linkage, and case–control association studies. However, traditional linkage analyses have been confounded by extreme phenotypic heterogeneity. In the search of candidate regions for PCOS, many studies were carried out. Follistatin gene was sequenced but subsequent linkage and association studies yielded negative results. A vigorous debate is under consideration about whether PCOS is fundamentally a neuroendocrine or ovarian disorder. Evidence is accumulating in favor of the latter. Thus, it seems that PCOS creates genetic complications and causes abnormalities such as steroidogenesis.

It is concluded that different results report the relationship of genes to the risk of PCOS. The mutations concerning PCOS have not been analyzed extensively particularly its effect on the phenotype. Thus, the future researchers must focus on addressing the mutations of PCOS and its impact on phenotype. The complications in the treatment follow an irregular pattern and they require a patient-centered approach and examination.

### Reducing complications of the disease

Polycystic ovarian syndrome which is also known as metabolic syndrome is associated with short-term and long-term complications ranging between obesity hirsutism, menstrual problem, fertility issues and endometrial carcinoma and diabetes mellitus. The reproductive system can be improved by weight loss and a dietary pattern in order to influence insulin resistance. A lifestyle that reduces obesity and IR is the major step to follow by patients with PCOS because even 5% of weight loss can make a significant change. It would also be beneficial to keep track of the situation and provide the patients the safety and therapeutic dietary plans for the recovery procedure. The biosynthesis of CYP11A breaks down the chain of polymerase using the PCR technique which enables the synthesis of accumulated cholesterol and limits a steroid synthetic hormone pathway.

### Conclusion

The current study aimed to determine the association of follistatin and cytochrome p450 side-chain cleavage enzyme (CYP11A) in polycystic ovarian syndrome (PCOS). The study targeted the Pakistani population. A sample of 62 participants based on 6 families was collected to obtain data and analyze it in context with CYP11A and PCOS. Furthermore, the findings showed a strong association of polycystic ovarian syndrome (PCOS) locus at chromosome 5 with marker D5S822 in family 2. The POCS possesses the ability to generate complications in
Nazir, et al.: Association of binding proteins and cleavage enzyme with PCOS
genetics resulting in abnormalities such as steroidogenesis. The study concluded that treatment and diagnosis complications are a major concern in Pakistan and require a more patient-centered approach to treat the disorder and eliminate the complications. Hence, future medical researchers should pay more attention to addressing the mutations of PCOS and its effect on the phenotype. The study also signifies the sensitivity of the relationship between PCOS and the insulin gene marker (D19S884) that is vitally involved in the gender susceptibility in the ovaries. Multiple genes have been examined for the study of PCOS but none of them seem to play a part in PCOS. However, the candidate genes INS VNTR and CYP11A were observed as the encoders of P450 chain cleavage.

Limitations and future direction
Certain limitations hurdle up while investigating genotypes and phenotypes of the PCOS cases, like, the ongoing need for research on diagnostic methods to the complexities associated with PCOS. Another complication is allocating the visible status of women diagnosed with PCOS and showed inflated responses. There are many clinical and biochemical manifestations advised for the phenotype, primarily irregular menstrual flow, baldness and weight gain, insulin resistance and increased androgens. The minor statistics results were observed in the study due to the smaller size of the sample design of the targeted women population. However, more related studies are required to examine the genotype and phenotype associations of PCOS with specific gene linkages and gene sequencing and development of gene therapy for this syndrome. The knowledge relates to humans and genes is escalating more frequently. With the aid of advanced biotechnological techniques and the discovery of novel polymorphisms, there is a possibility of complete mapping of the PCOS locus in the near future. These types of studies will also provide a new way to investigate early PCOS diagnosis in women, screening families with the possibility of PCOS, and measuring complications associated with PCOS in women.

Acknowledgments

The author is thankful to HEC (Higher Education Commission) Pakistan for funding the current project. It is worthy to acknowledge the full support and supervision of Dr. Samina Jalali (Ex-Chairperson, Department of Biological Sciences, QAU, Islamabad) and Dr. Raheel Qamar (Director PCR Lab, Shifa College of Medicine, current Rector, COMSATS Institute of Information Technology) throughout the project.

Authors’ Declaration Statements

Ethical approval
The study was carried out after taking ethical approval from the IRB (institutional review board) of Shifa international hospital Islamabad, Pakistan on 29.04.2004 with reference number IRB# 005-03-04. The study was carried on the 62 individuals and the duration of study was 2 years.

Ethical Consent
No author conducted research using animals. All operations involving human subjects were authorized by the institutional committee ethical standards and in line with the Helsinki Declaration (1964) and its subsequent revisions.

Patient’s Consent Statement
Consent was taken before going to conduct this study.

Availability of Data and Material
Data will provide on request.

Competing Interests
There author declares no conflict of interest.

Funding Statement
None

Authors’ Contributions
All authors have contributed equally in design, data collection, manuscript preparation, and revision. All authors agreed on the results and therefore approved the final version of the manuscript.

References
1. Legro RS, Strauss JF. Molecular progress in infertility: Polycystic ovary syndrome. Fertil Steril 2002;78:569-76.
2. Sattar N, Hopkinson ZE, Greer IA. Insulin-sensitising agents in polycystic-ovary syndrome. Lancet 1998;351:305-7.
3. Young RL, Goldzieher JW. Clinical manifestation of polycystic ovarian disease. Endocrinol Metab Clin North Am 1988;17:560-74.
4. Crum CP, Lester SC, Cotran RS. The female genital system and breast. Robbins Basic Pathol 2003;7:679-717.
5. Ardaens Y, Robert Y, Lemaitre L, Fossati P, Dewailly D. Polycystic ovarian disease: Contribution of vaginal endosonography and reassessment of ultrasonic diagnosis. Fertil Steril 1991;55:1062-8.
6. Wallach EE, Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988;50:197-212.
7. Barnes RB. The pathogenesis of polycystic ovary syndrome: Lessons from ovarian stimulation studies. J Endocrinol Invest 1998;21:567-79.
8. Fauser. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
9. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, et al. Thirty-seven candidate genes for polycystic ovary
syndrome: Strongest evidence for linkage is with follistatin. Proc Natl Acad Sci 1999;96:8573-8.
10. Cooper HE, Spellacy WN, Prem KA, Cohen WD. Hereditary factors in the Stein-Leventhal syndrome. Am J Obstet Gynaecol 1968;100:371-87.
11. Ferriman D, Purdie AW. The inheritance of polycystic ovarian disease and a possible relationship to premature balding. Clin Endocrinol (Oxf) 1979;11:291-300.
12. Givens JR. Familial polycystic ovarian disease. Endocrinology Metab Clin North Am 1988;17:771-83.
13. Hague WM, Adams J, Reeders ST, Peto TE, Jacobs HS. Familial polycystic ovaries: A genetic disease? Clin Endocrinol 1988;6:593-605.
14. Lunde O, Magnus P, Sandvik L, Høglo S. Familial clustering in the polycystic ovarian syndrome. Gynecol Obstet Invest 1989;28:23-30.
15. Carey AH, Chan KL, Short F, White D, Williamson R, Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf) 1993;38:653-8.
16. Gharani N, Waterworth DM, Batt S, White D, Gilling-Smith C, Conway GS, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397-402.
17. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999;28:361-78.
18. Lorez TC. Polymerase chain reaction: Basic protocol plus trouble shooting and optimization strategies. J Vis Exp 2012; 63:3988.
19. Ninfa AJ, Ballou DP. Fundamental Laboratory Approaches for Biochemistry and Biotechnology. In: Hoboken NJ, editor. Hoboken: Wiley and Sons; 2004.
20. Conway GS, Avey C, Rumshy G. Genetics: The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome. Hum Reprod 1994;9:1681-3.
21. Talbot JA, Bicknell EJ, Rajkhowa M, Krook A, O’Rahilly S, Clayton RN. Molecular scanning of the insulin receptor gene in women with the polycystic ovarian syndrome. J Clin Endocrinol Metabol 1996;81:1979-83.
22. Waterworth DM, Bennett ST, Gharani N, McCarthy MI, Hague S, Batt S, et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997;349:986-90.
23. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-48.
24. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metabol Clin North Am 1999;28:341-59.
25. Roldán B, San Millán J, Escobar-Morreale HF. Genetic basis of metabolic abnormalities in polycystic ovary syndrome. Am J Pharmacogenomics 2004;2:93-107.
26. Bennett RL, Steinhaus KA, Uhrich SB, O’Sullivan CK, Resta RG, Lochner-Doyle D, et al. Recommendations for standardized human pedigree nomenclature. J Genet Couns 1995:4:267-79.
27. Sambrooke J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. New York: Cold Spring Harbor Press; 1989.
28. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, Tsianateli TC, Kouli CR. Microsatellite polymorphism (ttta) n at-528 base pairs of gene CYP11α influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 2000;73:735-41.
29. Tucci S, Futterweit W, Concepcion ES, Greenberg DA, Villanueva R, Davies TF, et al. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metabol 2001;86:446-9.
30. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401-19.
31. Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol 2002;147:717-25.
32. Urbanek M, Spielman RS. Genetic analysis of candidate genes for the polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes 2002;9:492-501.
33. Odunsi K, Kidd KK. A paradigm for finding genes for a complex human trait: Polycystic ovarian syndrome and follistatin. Proc Natl Acad Sci U S A 1999;96:8315-7.
34. Liao WX, Roy AC, Ng SC. Preliminary investigation of follistatin gene mutations in women with polycystic ovary syndrome. Mol Hum Reprod 2000;6:587-90.
35. Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999;13:946-57.